Priced for a smaller company: management is quietly telling investors the business has already outgrown what the numbers
The model's full reasoning — Q4 2016 call → NOWe need to determine if management conveys that outsiders are currently underweighting something the company has already done, and points to a concrete, already-in-place thing whose contribution is still ahead. Let's analyze the transcript. Key points from Stuart Rothstein's remarks: - 2016 was active, completed acquisition of Apollo Residential Mortgage, originated over $1.4B investments, grew equity market cap to over $2B. - Operating earnings for 2016 excluding merger expenses totaled $148M, 32% increase. Per share $2.02, 6% increase, 1.10x coverage of dividend. - Completed over $1.2B new investments, funded incremental $140M. Portfolio grew 27% to over $3B. 87% floating rate loans. - Weighted average LTV 63%, expected levered IRR 13.8%. - Notable trends: increased first mortgage loan portfolio to $1.6B from less than $1B. 60% of loan portfolio is senior loans. Originated 10 floating rate first mortgage loans average size $85M, rate LIBOR+600bps. Using leverage, IRR low-to-mid teens. - 83% of loans directly originated, over 60% repeat borrowers. - Two condominium loans repaid, realized IRRs 11% and 13.5%. - CMBS holdings decreased by over $135M, now $368M, 12% of assets, 5% of net equity. AJ bonds 7% of assets, less than 4% of net equity. - In December, completed offering of 10.5M shares, raised $180M at 6% premium to book value. Capital raise and AMTG transaction represent over $600M of equity issued in 2016. Equity market cap surpassed $2B. - Expanded funding capacity: upsized JPMorgan facility to $800M, new $300M Deutsche Bank facility. - 2017 outlook: favorable economic climate, peak year for maturities, dry powder. Since January, closed $200M new investments, optimistic pipeline. Low leverage allows adding debt. Jai Agarwal's remarks: - Q4 operating earnings $41M or $0.49/share vs $32.4M or $0.48 in 2015. GAAP net income $49.7M or $0.60 vs $21.4M or $0.32. - Sold remainder of AMTG assets for $34M, realized gain $5.3M. Loss on CMBS bond sale $1.2M. - Full-year operating earnings excluding merger expenses $148M or $2.02 vs $113M or $1.90. - Book value increased from $15.94 to $16.12. - Leverage 1.0x debt-to-common equity. Used December capital raise to pay down JPMorgan facility, enter 2017 with capacity on both facilities. - G&A expense ratio flat, 40 bps. - 87% floating rate loans.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| KEY | KeyCorp | Q3 2022 | 2022-10-20 | B+ |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
PRPH · Q1 2023 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES The transcript shows management explicitly framing the current market view as mismatched with the company's actual position: "Anybody that's focused on us for earnings, you invested or are following the wrong company," "we're not an earnings story this year," and "focus less on revenues and earnings. This is a transition year." They repeatedly contrast this with the multi-billion-dollar assets already built and operating, whose contributions are still ramping or largely ahead. Concrete already-real items with meaningful payoff still ahead include: - The manufacturing facility (already at capacity, running nearly 100% YoY growth, with $25M revenue target for 2024 constrained only by capacity expansion this year; estimated $70M valuation next year plus $40M working capital and tens of millions in equipment). - Nebula Genomics (already generating >100% YoY revenue growth via direct-to-consumer sales; in-house whole-genome processing and B2B ramp expected in H2 202 3, particularly Q4, after validations complete in a couple of months).
KEY · Q3 2022 → YESThe question is: Does management convey that OUTSIDERS ARE CURRENTLY UNDERWEIGHTING SOMETHING THE COMPANY HAS ALREADY DONE — and does management answer that gap by pointing to at least one CONCRETE, A...YES Management repeatedly frames its interest-rate-risk positioning as something that “sets Key apart” and creates “unique and significant upside” that is not yet reflected in the market’s view of the company. Chris Gorman states that the $1.2 billion annualized benefit from re-pricing existing short-term Treasuries and swaps “ even in the event that rates remain at current levels” will arrive over the next two years, and Don Kimble confirms the same mechanics and timing. The $9 billion in short-term Treasuries and $26 billion in swaps are already on the balance sheet; the contribution is simply not yet in the reported results.
KIM · Q2 2018 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES Management explicitly frames the public-private pricing disconnect as a gap in how the company is valued versus its actual assets and execution. They point to the already-completed Toys "R" Us liquidation process (22 boxes resolved into OpCo and PropCo leases, with seven OpCo leases already signed and seven PropCo under 18-24 month resolution) as a concrete, already-real item whose rent contribution is still largely ahead in the reported results, with the 70-80 bps impact on occupancy and same-site NOI expected to be recaptured in Q3 and beyond.